Net loss of Indoco Remedies reported to Rs 26.39 crore in the quarter ended December 2024 as against net profit of Rs 16.30 crore during the previous quarter ended December 2023. Sales declined 12.27% to Rs 402.45 crore in the quarter ended December 2024 as against Rs 458.75 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales402.45458.75 -12 OPM %2.9913.71 - PBDT-3.2355.18 PL PBT-31.9530.83 PL NP-26.3916.30 PL Powered by Capital Market - Live News

Indoco Remedies has allotted 65,700 equity shares under ESOP on 21 January 2025. With this allotment, the paid up equity share capital has increased to Rs. 18,44,95,810 (consisting of 9,22,47,905 equity shares of face value of Rs. 2 each).Powered by Capital Market - Live News

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 21 January 2025.Powered by Capital Market - Live News

Net loss of Indoco Remedies reported to Rs 9.57 crore in the quarter ended September 2024 as against net profit of Rs 35.08 crore during the previous quarter ended September 2023. Sales declined 9.06% to Rs 430.66 crore in the quarter ended September 2024 as against Rs 473.58 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales430.66473.58 -9 OPM %9.3515.07 - PBDT23.9867.69 -65 PBT-4.8446.28 PL NP-9.5735.08 PL Powered by Capital Market - Live News

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live News